Search
Close this search box.

French-German Novasep-PharmaZell Group invests EUR7.3M at Mourenx site

This new investment will support the growth of the Mourenx site and sustain the growing demand for production of active pharmaceutical ingredients (APIs), particularly the highly potent drugs (HPAPIs) used to treat cancer.

The Novasep-PharmaZell Group has announced a €7.3M investment for its Mourenx site (southwestern France), as part of a larger project supported by the “France Relance” Plan, to create a multipurpose pilot workspace within one of its production units.

This investment includes an upgrade of two existing 2000-liter reactors to optimize their versatility and functionality, together with the addition of a new 1500-liter reactor & Hastelloy filter-dryer. The new multi-purpose workshop will be equipped to produce batches ranging from 30 to 100 kg for clinical trials, process validation and commercial production of APIs for targeted therapies, with a focus on HPAPIs. 

“This major project to modernize and expand the Mourenx site demonstrates our new Group’s determination to pursue the strategy of industrial investments that we have been successfully deploying for several years”, says Jean Bléhaut, President of the CDMO Business Unit. “This is a clear and practical answer for our pharmaceutical customers, who face growing challenges to secure supply chains in the field of healthcare products, and particularly APIs.”

Since the completion of the Novasep-PharmaZell merger, announced on April 7th, the new Group’s strategy is focused on offering its customers greater competitiveness, secure supply chains, and full support throughout the life cycle of their products. Novasep offers flexible contract development & manufacturing (CDMO) solutions for small molecule APIs & biopharmaceuticals to innovators. PharmaZell is a market leader in the highly resilient and specialty API market where it has a diversified portfolio of over 70 APIs and enjoys leading industry positions in several products that treat respiratory, inflammatory, and liver diseases. Many of the company’s products require special handling procedures and/or technologies. Headquartered in Raubling/Rosenheim (near Munich), PharmaZell operates four state-of-the-art production and R&D sites in Germany, Italy, and India with over 900 employees globally – now under the umbrella of Novasep.

©EuropeanBiotechNews/gkä